Laura García‐Estévez

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley et al. · Journal of Clinical Oncology · 2018 · 519 citations · Full text

Medicine, Oncology, Pharmacology +17

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +15

Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley et al. · Journal of Clinical Oncology · 2015 · 163 citations

Medicine, Oncology, Pharmacology +17

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle et al. · Clinical Cancer Research · 2019 · 97 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial

Aditya Bardia, Marina Parton, Sherko Kümmel et al. · Journal of Clinical Oncology · 2018 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17